In studies where tirzepatide was assessed as monotherapy or combined with metformin and SGLT2 inhibitors, the occurrence of clinically significant (level 2 or severe) hypoglycaemia was rare [53,55,56,62], while hypoglycaemia was more common when tirzepatide was added to a sulfonylurea or insulin [58,59,63]. The gene discussed is SLC5A2; the disease is Hypoglycemia.